Aceragen

Aceragen is a biopharmaceutical company that focuses on rare, orphan diseases with no approved treatments. They are dedicated to developing therapies to help patients, and specialize in melioidosis and cystic fibrosis. In addition to their innovative treatments, Aceragen also provides services such as data collection and processing. They are positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023. What sets Aceragen apart from other businesses in the same industry is their commitment to their mission and dedication to helping those in need. They strive to provide the best care and treatments possible, and their services are tailored to meet the needs of their patients.